The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment

  • Joo, Hyung Joon (Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital) ;
  • Park, Ji-Young (Department of Clinical Pharmacology and Toxicology, Korea University Anam Hospital) ;
  • Hong, Soon Jun (Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital) ;
  • Kim, Kyoung-Ah (Department of Clinical Pharmacology and Toxicology, Korea University Anam Hospital) ;
  • Lee, Seung Hoon (Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital) ;
  • Cho, Jae-Young (Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital) ;
  • Park, Jae Hyoung (Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital) ;
  • Yu, Cheol Woong (Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital) ;
  • Lim, Do-Sun (Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital)
  • Received : 2016.07.14
  • Accepted : 2017.01.04
  • Published : 2018.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Although epigallocatechin-3-gallate (EGCG), which is found in high contents in the dried leaves of green tea, has been reported to have an anti-platelet effect, synergistic effects of EGCG in addition to current anti-platelet medications remains to be elucidated. Methods: Blood samples were obtained from 40 participants who took aspirin (ASA, n = 10), clopidogrel (CPD, n = 10), ticagrelor (TCG, n = 10) and no anti-platelet medication (Control, n = 10). Ex vivo platelet aggregation and adhesion under various stimulators were analyzed by multiple electrode aggregometry (MEA) and Impact-R systems. PAC-1 and P-selectin expressions in human platelets were analyzed by flow cytometry. Results: In MEA analysis, adenosine diphosphate (ADP) and thrombin receptor activating peptide (TRAP)-induced platelet aggregations were lower in the CPD and the TCG groups; arachidonic acid (AA)-induced platelet aggregation was lower in the ASA group, whereas collagen (COL)-induced platelet aggregations were comparable among four groups. EGCG significantly reduced ADP- and COL-induced platelet aggregation in dose-dependent manner (ADP, p = 0.04; COL, p < 0.01). There were no additional suppressions of platelet aggregation stimulated by AA in the ASA group, and by ADP in the CPD and TCG groups. Moreover, EGCG suppressed shear stress-induced platelet adhesion on Impact-R, and had no effect on P-selectin and PAC-1 expressions. Conclusions: Ex vivo treatment of EGCG inhibited platelet adhesion and aggregation without changes in P-selectin and PAC-1 expression. There was no additional suppressions in platelet aggregation stimulated by AA in the ASA group and ADP in the CPD and TCG groups.

Keywords

Acknowledgement

Supported by : Korea Health Industry Development Institute (KHIDI), National Research Foundation of Korea (NRF)

References

  1. D'Ascenzo F, Taha S, Moretti C, et al. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol 2015;115:1185-1193. https://doi.org/10.1016/j.amjcard.2015.02.003
  2. Jin HY, Yang TH, Choi KN, et al. Randomized comparison of the platelet inhibitory efficacy between low dose prasugrel and standard dose clopidogrel in patients who underwent percutaneous coronary intervention. Korean Circ J 2014;44:82-88. https://doi.org/10.4070/kcj.2014.44.2.82
  3. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574-e651. https://doi.org/10.1161/CIR.0b013e31823ba622
  4. Li J, Song M, Jian Z, et al. Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence. J Atheroscler Thromb 2014;21:239-247. https://doi.org/10.5551/jat.19521
  5. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787. https://doi.org/10.1055/s-0037-1613462
  6. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33. https://doi.org/10.1016/j.jacc.2005.08.058
  7. Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010;56:1447-1455. https://doi.org/10.1016/j.jacc.2010.03.103
  8. Cuisset T, Frere C, Quilici J, Uhry S, Alessi MC, Bonnet JL. Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment? Int J Cardiol 2010;138:212-213. https://doi.org/10.1016/j.ijcard.2008.06.044
  9. Shimizu M, Shirakami Y, Moriwaki H. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci 2008;9:1034-1049. https://doi.org/10.3390/ijms9061034
  10. Lee HS, Jun JH, Jung EH, Koo BA, Kim YS. Epigalloccatechin- 3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation. Molecules 2014;19:12150-12172. https://doi.org/10.3390/molecules190812150
  11. Sugisawa A, Umegaki K. Physiological concentrations of (-)-epigallocatechin-3-O-gallate (EGCg) prevent chromosomal damage induced by reactive oxygen species in WIL2-NS cells. J Nutr 2002;132:1836-1839. https://doi.org/10.1093/jn/132.7.1836
  12. Deana R, Turetta L, Donella-Deana A, et al. Green tea epigallocatechin- 3-gallate inhibits platelet signaling pathways triggered by both proteolytic and non-proteolytic agonists. Thromb Haemost 2003;89:866-874. https://doi.org/10.1055/s-0037-1613474
  13. Matsumura K, Takayama H, Bae JY, Kurihara M, Tsutsumi S, Hyon SH. Preservation of platelets by adding epigallocatechin-3-o-gallate to platelet concentrates. Cell Transplant 2009;18:521-528. https://doi.org/10.1177/096368970901805-606
  14. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008;99:121-126.
  15. Shenkman B, Matetzky S, Fefer P, et al. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thromb Res 2008;122:336-345. https://doi.org/10.1016/j.thromres.2007.10.018
  16. Scheer FA, Michelson AD, Frelinger AL 3rd, et al. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One 2011;6:e24549. https://doi.org/10.1371/journal.pone.0024549
  17. Chowdhury A, Sarkar J, Chakraborti T, Pramanik PK, Chakraborti S. Protective role of epigallocatechin-3-gallate in health and disease: a perspective. Biomed Pharmacother 2016;78:50-59. https://doi.org/10.1016/j.biopha.2015.12.013
  18. Sagesaka-Mitane Y, Miwa M, Okada S. Platelet aggregation inhibitors in hot water extract of green tea. Chem Pharm Bull (Tokyo) 1990;38:790-793. https://doi.org/10.1248/cpb.38.790
  19. Kang WS, Lim IH, Yuk DY, et al. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res 1999;96:229-237. https://doi.org/10.1016/S0049-3848(99)00104-8
  20. Joo SJ, Choi JH, Kim SY, Kim KS, Kim YR, Kang SH. An assay of measuring platelet reactivity using monoclonal antibody against activated platelet glycoprotein IIb/IIIa in patients taking clopidogrel. Korean Circ J 2015;45:378-385. https://doi.org/10.4070/kcj.2015.45.5.378
  21. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010;30:2341-2349. https://doi.org/10.1161/ATVBAHA.110.207522
  22. Kang WS, Chung KH, Chung JH, et al. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase. J Cardiovasc Pharmacol 2001;38:875-884. https://doi.org/10.1097/00005344-200112000-00009
  23. Ok WJ, Cho HJ, Kim HH, et al. Epigallocatechin-3-gallate has an anti-platelet effect in a cyclic AMP-dependent manner. J Atheroscler Thromb 2012;19:337-348. https://doi.org/10.5551/jat.10363
  24. Lill G, Voit S, Schror K, Weber AA. Complex effects of different green tea catechins on human platelets. FEBS Lett 2003;546:265-270. https://doi.org/10.1016/S0014-5793(03)00599-4
  25. Neuhaus T, Voit S, Lill G, Vetter H, Schror K, Weber AA. Platelet aggregation induced by the C-terminal peptide of thrombospondin-1 (4N1-1) is inhibited by epigallocatechin gallate but not by prostaglandin E1. Platelets 2004;15:455-457. https://doi.org/10.1080/09537100410001710245
  26. Lee DH, Kim YJ, Kim HH, et al. Inhibitory effects of epigallocatechin- 3-gallate on microsomal cyclooxygenase-1 activity in platelets. Biomol Ther (Seoul) 2013;21:54-59. https://doi.org/10.4062/biomolther.2012.075
  27. Iida Y, Doi T, Matsushima-Nishiwaki R, et al. (-)-Epigallocatechin gallate selectively inhibits adenosine diphosphatestimulated human platelet activation: suppression of heat shock protein 27 phosphorylation via p38 mitogenactivated protein kinase. Mol Med Rep 2014;10:1383-1388. https://doi.org/10.3892/mmr.2014.2389
  28. Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol 2011;72:647-657. https://doi.org/10.1111/j.1365-2125.2011.03999.x
  29. Wong AK. Platelet biology: the role of shear. Expert Rev Hematol 2013;6:205-212. https://doi.org/10.1586/ehm.13.5
  30. Frelinger AL 3rd, Grace RF, Gerrits AJ, et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood 2015;126:873-879. https://doi.org/10.1182/blood-2015-02-628461
  31. Floyd CN, Ferro A. Antiplatelet drug resistance: molecular insights and clinical implications. Prostaglandins Other Lipid Mediat 2015;120:21-27. https://doi.org/10.1016/j.prostaglandins.2015.03.011
  32. Sorensen R, Olesen JB, Charlot M, Gislason GH. Risk of bleeding related to antithrombotic treatment in cardiovascular disease. Curr Pharm Des 2012;18:5362-5378. https://doi.org/10.2174/138161212803251970
  33. Keske MA, Ng HL, Premilovac D, et al. Vascular and metabolic actions of the green tea polyphenol epigallocatechin gallate. Curr Med Chem 2015;22:59-69.
  34. Legeay S, Rodier M, Fillon L, Faure S, Clere N. Epigallocatechin gallate: a review of its beneficial properties to prevent metabolic syndrome. Nutrients 2015;7:5443-5468. https://doi.org/10.3390/nu7075230
  35. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005;81:230S-242S. https://doi.org/10.1093/ajcn/81.1.230S
  36. Williamson G, Dionisi F, Renouf M. Flavanols from green tea and phenolic acids from coffee: critical quantitative evaluation of the pharmacokinetic data in humans after consumption of single doses of beverages. Mol Nutr Food Res 2011;55:864-873. https://doi.org/10.1002/mnfr.201000631

Cited by

  1. Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism vol.85, pp.4, 2018, https://doi.org/10.1111/1750-3841.15096
  2. Predicting the effect of tea polyphenols on ticagrelor by incorporating transporter-enzyme interplay mechanism vol.330, pp.None, 2020, https://doi.org/10.1016/j.cbi.2020.109228
  3. Combination of natural antivirals and potent immune invigorators: A natural remedy to combat COVID‐19 vol.35, pp.12, 2018, https://doi.org/10.1002/ptr.7228